Enzymatics is a leading producer of sample preparation reagents, diagnostic assays, kits, and software for life science research and applied science customers worldwide. The company develops and manufacture enzymes, buffers, formulations and has a complete product portfolio that complements high value industrial PCR, NGS, SynBio markets. Their enzymes are used in over 75% of all sequencing reactions globally.
PBM Capital founded Enzymatics, operated and served on the Board until 2015 when we sold the business to Qiagen (NASDAQ:QGEN).